Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Current Assets (2016 - 2025)

Lisata Therapeutics' Current Assets history spans 13 years, with the latest figure at $17.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 48.8% year-over-year to $17.7 million; the TTM value through Dec 2025 reached $17.7 million, down 48.8%, while the annual FY2025 figure was $17.7 million, 48.8% down from the prior year.
  • Current Assets reached $17.7 million in Q4 2025 per LSTA's latest filing, down from $21.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $65.3 million in Q1 2023 to a low of $17.7 million in Q4 2025.
  • Average Current Assets over 3 years is $41.0 million, with a median of $39.8 million recorded in 2024.
  • Peak YoY movement for Current Assets: dropped 27.17% in 2024, then crashed 48.8% in 2025.
  • A 3-year view of Current Assets shows it stood at $53.9 million in 2023, then crashed by 35.88% to $34.6 million in 2024, then plummeted by 48.8% to $17.7 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Current Assets are $17.7 million (Q4 2025), $21.6 million (Q3 2025), and $24.9 million (Q2 2025).